Olopatadine inhibits TNFα release from human conjunctival mast cells

Annals of Allergy, Asthma and Immunology

Volumn 84, Issue 5, 2000, Pages 504-508

  Cook, Ellen B ^a   Stahl, James L ^a   Barney, Neal P ^a   Graziano, Frank M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLOPATADINE; TUMOR NECROSIS FACTOR ALPHA; ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; DIBENZOXEPIN DERIVATIVE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONJUNCTIVITIS; DRUG EFFECT; HUMAN; HUMAN CELL; MAST CELL; PRIORITY JOURNAL; CONJUNCTIVA; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM;

ANTIBODIES, ANTI-IDIOTYPIC; CONJUNCTIVA; DIBENZOXEPINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; MAST CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033625234     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62513-6     Document Type: Article

References (16)

1. Cook EB, Stahl JL, Miller ST, et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-α from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest Ophtalmol Vis Sci 1998;39(2): 336-343.
2. Barney NP, Cook EB, Stahl JL, et al. Human conjunctival mast cells (HCMC) release and express message for TNFa in response to anti-IgE challenge in a time and dose dependent manner. J Allergy Clin Immunol 1999; 103:S41.
3. Dunnet CW. A multiple comparison procedure for comparing treatments with a control. J Am Stat Assoc 1955; 50:1096-1121.
4. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997;79:541-545.
5. Sharif NA, Xu SX, Miller ST, Gamache DA, et al. Characterization of ocular anti-allergic and anti-histaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996; 278:1252-1261.
6. Okayama Y, Kobayashi H, Ashman LK, et al. Activation of eosinophils with cytokines produced by lung mast cells. Int Arch Allergy Immunol 1997; 114 Suppl 1:75-77.
7. Gibbs BF, Arm JP, Gibson K, Lee TH, et al. Human lung mast cells release small amounts of interleukin-4 and tumour necrosis factor-alpha in response to stimulation by anti-IgE and stem cell factor. Eur J Pharmacol 1997;327: 73-78.
8. Gamache D, Dimitrijevich S, Weimer L, et al. Secretion of proinflammatory cytokines by human conjunctival epithelial cells. Ocular Immunol Inflam 1997;5:117-128.
9. Fukagawa K, Saito H, Tsubota K, et al. RANTES production in a conjunctival epithelial cell line. Cornea 1997;16: 564-567.
10. Takano Y, Fukagawa K, Saito H, et al. Synthesis of IL-8, RANTES, and MCP-1 in human conjunctival and corneal epithelial primary cultures. Invest Ophthalmol Vis Sci 1998;39:S546.
11. - lergy Immunol 1998;115:288-293.
12. Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol 1988;66:381-386.
13. Bagnasco M, Pesce G, Fiorino N, et al. In situ hybridization analysis of ICAM-1 (CD54) mRNA on conjunctival epithelium during allergic inflammation. Clin Exp Allergy 1997;27: 737-743.
14. Pavilack MA, Einer VM, Einer SG, et al. Differential expression of human corneal and perilimbal ICAM1 by inflammatory cytokines. Invest Ophthalmol Vis Sci 1992;33:564-573.
15. Kaminska GM, Niederkorn JY, McCulley JP. Multi functional cytokine expression by human mast cells: regulation by T cell membrane contact and glucocorticoids. Invest Ophthalmol Vis Sci 1991;32:677.
16. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;11:643-647.